Objectives: A significant and sustained paradigm shift in abdominal aortic aneurysm treatment toward endovascular technology has come at a cost of open surgical procedures despite similar long-term survival. We sought to determine morbidity and mortality rate in patients undergoing open surgical repair (OSR) for abdominal aortic aneurysms at a single high-volume open regional center.
PC006.
Fenestrated and Chimney Endovascular versus Open Repair of Juxtarenal, Pararenal and Suprarenal Abdominal Aortic Aneurysms: A 5-Year National Study (2012) (2013) (2014) (2015) (2016) (2012) (2013) (2014) (2015) (2016) were included. Any emergent, ruptured, and thoracoabdominal aortic aneurysms were excluded from the study. Univariate (c 2 test, analysis of variance) and multivariate logistic regression statistical analysis were used as appropriate.
Results: A total of 1191 patients were identified, of whom the majority underwent OAR (72%) compared with Ch-EVAR (14%) and FEVAR (14%). Patients undergoing OAR were slightly younger compared with FEVAR and Ch-EVAR (mean age, 71.3 6 7.8 years vs 74.1 6 7.9 years and 74.7 6 82 years, respectively; P < .001). Patients comorbidities were similar between the three groups. The total operation time was higher in patients undergoing FEVAR compared with OAR and Ch-EVAR (mean 270.49 6 100.73 minutes vs 258.89 6 111.89 minutes and 226.95 6 110.67 minutes, respectively; P ¼ .0006). OAR compared with FEVAR and Ch-EVAR, had a longer duration of hospital stay, transfusion, and return to the operating room (Table I) . In a univariate analysis, 30-day mortality was similar between the three approaches. However, the risk of renal failure, cardiopulmonary failure, and surgical site infections was significantly higher in patients undergoing OAR compared with FEVAR and Ch-EVAR (Table I) . After adjusting for potential confounders, compared with any endovascular repairs, OAR was associated with a two-fold increased risk of mortality (odds ratio [OR], 2.00; 95% confidence interval [CI], 1.01-3.93), a three-fold increased risk of renal failure (OR, 2.96; 95% CI, 1.53-5.73), and a six-fold increased risk of cardiopulmonary failure (OR, 6.19; 95% CI, 3.44-11.13; all P < .05; Table II ). In a subset multivariate logistic regression analysis looking at only endovascular repairs, no difference was seen in mortality between FEVAR and Ch-EVAR. However, the risk of renal failure was six-fold higher in patients undergoing Ch-EVAR compared with FEVAR (OR 6.45; 95% CI, 1.12-37.23; P ¼ .04).
Conclusions: Using a contemporary large national vascular-targeted dataset, we demonstrated 2-fold higher mortality and three-to six-fold higher morbidities risk in patients undergoing open versus endovascular repair of AAA involving the renal vessels. Compared with FEVAR, Ch-EVAR was associated with a six-fold increased risk of developing postoperative renal failure. FEVAR is the safer approach, especially when managing older patients with juxtarenal, pararenal, and suprarenal aneurysms. Table I . Thirty-day postoperative outcomes in patients undergoing repair of juxtarenal, pararenal and suprarenal abdominal aortic aneurysms Objectives: Wide variation in practice continues to exist regarding the necessity of revascularization of the left subclavian artery among patients who undergo elective thoracic endovascular aortic repair (TEVAR) with coverage of the left subclavian artery. This study aims to analyze the outcomes of TEVAR with concomitant carotid-subclavian bypass versus TEVAR alone among patients whose left subclavian artery is covered.
Methods: A retrospective analysis of prospectively collected data was performed using the National Surgical Quality Improvement Program for patients undergoing nonemergent TEVAR with coverage of the left subclavian artery from 2012 to 2016. Demographics, comorbidities, and 30-day outcomes were compared among patients who underwent TEVAR with and without concomitant carotid subclavian bypass. Multivariable analysis was used to adjust for differences in demographic and operative characteristics.
Results: A total of 603 patients underwent nonemergent TEVAR with coverage of the left subclavian artery: 130 with concomitant carotid-subclavian bypass and 473 without. Other than a slightly older population in the group without a bypass (68 years vs 66 years; P ¼ .047), there were no significant differences in baseline demographics or comorbidities between the two groups. Patients with concomitant carotid-subclavian bypass had a significantly higher risk of stroke (7.7% vs 2.8%; P < .01), 
